James Newman, MD
Plastic Surgery · Palo Alto
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Newman’s office at (650) 321-7100 to ask if they take your plan before you enroll.
California Medical Board record
Licence G75022 · Current
Licensed to practise in California · since 1992 · expires 2028-03-31 · University of Texas Medical Branch at Galveston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Facial Plastic & Reconstructive Surgery - Facial Plastic & Reconstructive Surgery
- American Board of Otolaryngology - Otolaryngology
Drugs they prescribed that Part D paid
$2,045
Pharmacies billed $2,045 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 14% of their Part D prescriptions (22 of 159) in 2024. At or below the middle of the specialty; the typical plastic surgery clinician is at 21%. Surgeons prescribe little besides pain medicine after an operation, so their opioid share runs high.
150 generic and fewer than 11 brand-name prescriptions · $2,045 in drug cost · 40 antibiotic prescriptions to 39 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Valacyclovir | 21 | $370 | $17 |
| Neomycin-Polymyxin-Dexameth | 11 | $318 | $13 |
| Cephalexin | 37 | $234 | $6 |
| Celecoxib | 13 | $192 | $14 |
| Hydrocodone-Acetaminophen | 16 | $169 | $11 |
See all 6 drugs
| Valacyclovir | 21 | $370 | $17 |
| Neomycin-Polymyxin-Dexameth | 11 | $318 | $13 |
| Cephalexin | 37 | $234 | $6 |
| Celecoxib | 13 | $192 | $14 |
| Hydrocodone-Acetaminophen | 16 | $169 | $11 |
| Ondansetron Odt | 12 | $87 | $7 |
Year by year
| 2024 | 159 | 48 | 14% (22) | None | $2,045 |
| 2023 | 115 | 51 | 16% (18) | None | $1,937 |
| 2022 | 112 | 40 | 22% (25) | None | $1,343 |
| 2021 | 77 | 31 | 23% (18) | None | $1,144 |
| 2020 | 79 | 31 | 24% (19) | None | $1,292 |
| 2019 | 118 | 42 | 21% (25) | None | $1,558 |
| 2018 | 61 | 27 | 20% (12) | 0% | $1,499 |
| 2017 | 58 | 25 | 24% (14) | None | $1,381 |
| 2016 | 62 | 25 | 26% (16) | None | $1,696 |
| 2015 | 57 | 26 | 30% (17) | 0% | $699 |
| 2014 | 56 | 25 | 21% (12) | None | $1,455 |
| 2013 | 53 | 21 | 28% (15) | 0% | $614 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Valacyclovir | 26 | $444 | $17 |
| Cephalexin | 33 | $274 | $8 |
| Hydrocodone-Acetaminophen | 15 | $111 | $7 |
2022: 3 drugs
| Valacyclovir | 20 | $369 | $18 |
| Cephalexin | 31 | $195 | $6 |
| Hydrocodone-Acetaminophen | 15 | $139 | $9 |
2021: 3 drugs
| Valacyclovir | 18 | $437 | $24 |
| Cephalexin | 23 | $105 | $5 |
| Hydrocodone-Acetaminophen | 12 | $89 | $7 |
2020: 2 drugs
| Cephalexin | 17 | $105 | $6 |
| Hydrocodone-Acetaminophen | 11 | $94 | $9 |
2019: 3 drugs
| Valacyclovir | 26 | $405 | $16 |
| Cephalexin | 33 | $175 | $5 |
| Hydrocodone-Acetaminophen | 23 | $159 | $7 |
2018: 2 drugs
| Valacyclovir | 13 | $174 | $13 |
| Cephalexin | 14 | $91 | $6 |
2017: 3 drugs
| Valacyclovir | 11 | $149 | $14 |
| Cephalexin | 16 | $94 | $6 |
| Hydrocodone-Acetaminophen | 13 | $53 | $4 |
2016: 2 drugs
| Hydrocodone-Acetaminophen | 13 | $135 | $10 |
| Cephalexin | 24 | $128 | $5 |
2015: 2 drugs
| Hydrocodone-Acetaminophen | 17 | $121 | $7 |
| Cephalexin | 20 | $70 | $3 |
2014: 1 drug
| Cephalexin | 14 | $68 | $5 |
2013: 2 drugs
| Hydrocodone-Acetaminophen | 15 | $108 | $7 |
| Cephalexin | 14 | $82 | $6 |
Money from drug and device companies
$101 in 2025
| 2025 | 2 | 5 | $14 | $101 |
| 2024 | 4 | 34 | $948 | $2,346 |
| 2023 | 3 | 25 | $4,410 | $5,132 |
| 2022 | 5 | 13 | None | $994 |
| 2021 | 4 | 44 | $3,105 | $5,728 |
| 2020 | 2 | 24 | None | $541 |
| 2019 | 3 | 43 | None | $1,074 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
BlackSwan Vascular, Inc.
$212,918
Held by this doctor · 2022, 2021 · Preferred Stock Ownership, Equity Investment · amount invested $212,918
PROCEPT BioRobotics Corporation
$688,557
Held by this doctor · 2020, 2019 · Preferred Stock and Warrants To Purchase Preferred Stock · amount invested $10,095
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Merz North America | Xeomin | $51 | 2 payments
|
| Abbvie | Botox | $50 | 3 payments
|
See all 5 published payments
| Merz North America | Meals · 2025-11-12 | None | $28 |
| Abbvie | Paid to speak or teach · 2025-10-08 | None | $14 |
| Abbvie | Meals · 2025-08-07 | Botox | $22 |
| Abbvie | Meals · 2025-04-17 | None | $14 |
| Merz North America | Meals · 2025-02-18 | Xeomin | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,346
| Abbvie | Botox | $1,743 | 22 payments
|
| Galderma Laboratories L.P. | None | $228 | 2 payments
|
| Revance Therapeutics | Daxxify | $211 | 3 payments
|
| Merz North America | Xeomin | $164 | 7 payments
|
2023: $5,132
| Abbvie | Botox | $4,895 | 14 payments
|
| Merz North America | Xeomin | $143 | 7 payments
|
| Galderma Laboratories L.P. | Dysport | $95 | 4 payments
|
2022: $994
| Merz North America | None | $627 | 3 payments
|
| Allergan | Botox | $246 | 4 payments
|
| Galderma Laboratories L.P. | None | $59 | 3 payments
|
| Baxter Healthcare | Artiss | $34 | 2 payments
|
| Trevena | Olinvyk | $28 | 1 payment
|
2021: $5,728
| Allergan | Botox | $3,588 | 20 payments
|
| Merz North America | Xeomin | $1,969 | 17 payments
|
| Galderma Laboratories L.P. | None | $121 | 6 payments
|
| PolarityTE | None | $50 | 1 payment
|
2020: $541
| Galderma Laboratories L.P. | None | $336 | 10 payments
|
| Merz North America | Xeomin | $205 | 14 payments
|
2019: $1,074
| Galderma Laboratories L.P. | None | $518 | 12 payments
|
| Merz North America | Xeomin | $299 | 21 payments
|
| Allergan | Botox Cosmetic | $257 | 10 payments
|
Professional record
- NPI
- 1619012762
- Licence
- CA G75022California G75022: Current · expires 2028-03-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 208200000X (208200000X); Federal specialty code 207YX0905X (207YX0905X)
- Mailing address
- 1795 El Camino Real, Suite 200, Palo Alto, CA, 94306
- NPI first listed
- 2007-02-20
- NPI last updated
- 2025-05-11
- NPI record certified
- 2025-05-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 316 S Eldorado St Ste 105, San Mateo, CA, 94401